

WORLDWIDE APPROVAL

TRIUMEQ Tablets

Albania	Guatemala	New Zealand
Argentina	Guyana	Nigeria
Armenia	Haiti	Pakistan
Australia	Honduras	Panama
Azerbaijan	Hong Kong	Peru
Bahrain	Israel	Saudi Arabia
Bosnia and Herzegovina	Jamaica	Serbia
Botswana	Japan	Singapore
Brazil	Jordan	South Africa
Canada	Kazakhstan	South Korea
Chile	Kenya	Switzerland
China	Kuwait	Taiwan
Colombia	Kyrgyzstan	Thailand
Costa Rica	Lebanon	Turkey
Curacao	Macau	Uganda
Dominican Republic	Macedonia	Ukraine
Ecuador	Mexico	United Arab Emirates
El Salvador	Moldova	United States of America
European Union	Mongolia	Uruguay
Georgia	Morocco	Uzbekistan
Ghana	Namibia	

- ✓ **"Approval" means: Marketing Authorisation has been granted by a country or there is no formal regulatory process in place, in the relevant country.**
- ✓ **Granted Marketing Authorisations may include limitations on the use of the product.**

This document was prepared on 12 July 2019 and will be updated on a quarterly basis by ViiV Healthcare. It is made available for information purposes only and ViiV Healthcare accepts no liability arising from the reliance by third parties, on the information provided.